Mutant protein of osteoprotegerin, as well as relevant product and application thereof
A technology of osteoprotegerin and related products, applied in the fields of application, peptide/protein composition, animal/human protein, etc., can solve problems that affect clinical application and increase tumor risk
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0107] Example 1. Preparation of wild-type human osteoprotegerin OPGwt and wild-type human osteoprotegerin mutant proteins OPGS73A, OPGS73V, OPGS73G, OPGS73L, OPGK94A and OPGR122G
[0108] 1. Preparation of wild-type human osteoprotegerin OPGwt
[0109] The amino acid sequence of wild-type human osteoprotegerin OPGwt is the 154th to 345th amino acid residues of SEQ ID No.2. Wild-type human osteoprotegerin OPGwt contains amino acid residues 22-201 of human full-length osteoprotegerin (amino acid sequence is GenBank AccessionNumber NP_002537.3 (26-JUN-2017) or SEQ ID No.9).
[0110] Wild-type human osteoprotegerin OPGwt was prepared according to the method of the following literature: Mengmeng Jin, et al. Sortase A-aided Escherichia coli expression system for functional osteoprotegerin cysteine-rich domain. Appl Microbiol Biotechnol (2017) 101:4923–4933. DOI10.1007 / s00253 -017-8188-6. The specific method is as follows:
[0111] 1.1 Preparation of DNA molecules
[0112] The D...
Embodiment 2
[0169] Example 2, Affinity Determination of Wild-type Human Osteoprotegerin OPGwt and Human Osteoprotegerin Mutant Proteins OPGS73A, OPGS73V, OPGS73G, OPGS73L, OPGK94A and OPGR122G with RANKL and TRAIL
[0170] The surface plasmon resonance (Surface Plasmon Resonance, SPR) technology was used, and the equipment used was BIAcore 3000 (GE Healthcare), and RANKL or TRAIL was used as the stationary phase to immobilize on a certain channel on the surface of the CM5 chip (diluted into 10mM sodium acetate pH5.5 ), the response value increased by about 2000RU is better; TNFRSF9 was fixed in another channel as an internal reference; the OPGwt prepared in Example 1 and the mutant proteins OPGS73A, OPGS73V, OPGS73G, OPGS73L, OPGK94A and OPGR122G of human osteoprotegerin were used as mobile phases, and BIAcore buffer (10mM HEPES, 150mM NaCl, 0.005% Tween 20, pH 7.4) prepared OPGwt and human osteoprotegerin mutant proteins OPGS73A, OPGS73V, OPGS73G, OPGS73L, OPGK94A and OPGR122G at differen...
Embodiment 3
[0182] Example 3, Biological activity of wild-type human osteoprotegerin OPGwt and mutant proteins OPGS73A, OPGS73V, OPGS73G, OPGS73L, OPGK94A and OPGR122G of human osteoprotegerin
[0183] 1. Inhibition of RANKL-mediated osteoclast activation experiment
[0184] The differentiation and maturation of RANKL-induced osteoclasts are marked by the formation of multinucleated cells and the expression of tartrate-resistant acid phosphatase (TRAP) in multinucleated cells.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com